Review of the Drug Trials Snapshots Program of the US Food and Drug Administration: Women in Cardiovascular Drug Trials
Over the last 20 years, there have been concerns that too few women and minorities are enrolled in clinical trials to provide confidence about drug safety and effectiveness. Women's advocacy groups, in particular, have called for more representation in trials of cardiovascular diseases. In 2012, the US Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA 907) was enacted and required the FDA to report on the diversity of participants in clinical trials and the extent to which safety and effectiveness data are based on demographic factors such as sex, race, and age. In response, the FDA piloted a new transparency initiative called the Drug Trials Snapshots Program. Snapshots are data posted online in a standardized format after approval of a "new molecular entity" (NME). They show who participated in the pivotal clinical trials used to approve the drug by sex, race, and age subgroups. Snapshots also provide statements on observed demographic subgroup differences in safety and efficacy. The FDA releases a Snapshot for every NME approved after January 2015 within 30 days of the approval date.
Methods | Reviewing the first year of Snapshot data from January 1, 2015, through December 31, 2015, we documented the reported number of women in cardiovascular drug trials and whether any statements of subgroup difference were made. We compared the sex-specific safety and efficacy statements in Snapshots (http://www.fda.gov/Drugs/InformationOnDrugs /ucm412998.htm) with those made in the corresponding prescribing information (PI) accessed on Drugs@FDA: FDA Approved Drug Products (http://www.accessdata.fda.gov /scripts/cder/daf/) (and also linked on the Snapshots page).
Results | In 2015, there were 9 NMEs with cardiovascular indications. Of these, the number of women enrolled in the trials Editor's Note page 727 Table 1) .
1-5 Inclusion of women ranged from 24 participants to 8006 (mean of 2262 and median of 1691). Nine Snapshot statements concluded that men and women responded similarly. Seven PI statements concluded that men and women responded similarly, and 2 did not provide efficacy statements on sex. Two Snapshot statements concluded that there were safety differences between men and women; 6 concluded that the risk of adverse effects appeared to be similar in men and women; and 1 concluded there were not enough participants to determine the difference. The PI did not include any statements on adverse effects differences between men and women ( Table 2) .
Discussion | Previous investigations into the number of participants by sex were limited to aggregate data and broad therapeutic area. 6 The FDA Drug Trials Snapshots Program represents the first time that pivotal trial demographic information and subgroup analysis statements for safety and efficacy of all newly approved NMEs are consistently reported and readily available in 1 place. Cardiovascular disease appears to be an area where enrollment of women is disproportionately low. The FDA plans to work with the cardiology community to address this issue. A comparison of the statements made in Snapshots and PI statements shows more consistency in efficacy statements than safety statements. For the 2015 cardiovascular NMEs, Snapshots documented 2 safety statements related to increased bleeding risk and 1 statement where there were not enough participants to determine the difference, whereas the PI did not have any sex subgroup statements related to safety. These differences may be owing to the legal requirements imposed on the PI, for which sex demographic labeling is not a required subsection.
With only a year's worth of Snapshot data, we are limited in understanding if these data are comparable to those of other years. Beyond the demographics of sex, variability in response to drugs may also be caused by a large number of factors including diet, concomitant medications, genetic traits, and other factors. As a transparency initiative, the Snapshots Program intends to catalyze a broader discussion on ways to improve our understanding of biologic The risk of adverse effects was similar in men and women
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In a population pharmacokinetic analysis, after accounting for body weight, sex had no additional clinically significant effect on edoxaban pharmacokinetics The 2012 FDA Safety and Innovation Act 3 directed the FDA to assess the inclusion, analysis, and public reporting of demographic subgroups-including by sex-in new drug, biologic, and device applications and to formulate an action plan to improve trial participation and data quality and transparency. As part of its response, the FDA has implemented Drug Trials Snapshots (DTS) for drugs approved beginning January 2015. The DTS program is a substantial step forward because the demographic characteristics of clinical trial participants are posted along with notes as to whether there were any differences in safety or efficacy by group, including sex. In this issue, Whyte and his FDA colleagues 4 review all 9 cardiovascular drugs approved during the first year of DTS, and found that women accounted for slightly more than onethird of study participants. All DTS noted similar efficacy by sex, but only 6 (67%) concluded similar safety profiles by sex. The increased transparency offered by DTS is a great step forward, and it would be even more helpful to include drugs approved prior to 2015 as well as medical devices. Drug prescribing information is available on labels, but this information is more limited than DTS and can be hard to access for patients and physicians.
How can we continue this FDA effort to improve availability of information on sex-specific risks and benefits for drugs and devices? There should be transparent tracking of demographics in premarket clinical trials of drugs and devices; such data should be examined at regular intervals to ensure that a representative patient population is being enrolled prior to application for FDA approval. New drug or device applications submitted for FDA approval with insufficient or nonrepresentative numbers of women should be returned until the drug or device sponsor has adequate safety and effectiveness data in both sexes. As documented by DTS, progress in the last 30 years has been slow, and meaningful changes will require FDA action and consequences for noncompliance; such steps are urgently needed to ensure that the benefits outweigh risks for approved drugs and devices in both women and men.
